Loading
New York oncologist who was lead author of the KRYSTAL-1 colorectal report, which showed adagrasib with cetuximab shrinks KRAS G12C-mutant colorectal cancer and led to the combination's approval.
Rona Yaeger is a gastrointestinal medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center. She was first author of the 2023 New England Journal of Medicine report of the KRYSTAL-1 cohorts in which adagrasib alone and with cetuximab produced responses in heavily pretreated KRAS G12C-mutant metastatic colorectal cancer, the basis of the combination's accelerated approval. Her laboratory studies mechanisms of resistance to RAS and BRAF inhibitors.
| Title | Journal | Year |
|---|---|---|
| KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer | New England Journal of Medicine | 2023 |
Adagrasib plus cetuximab is an approved option for previously treated KRAS G12C colorectal cancer, alongside sotorasib plus panitumumab; monotherapy is not enough because EGFR signalling reactivates the pathway.
It turned sidedness from an epidemiological curiosity into a mechanistic statement, and it is the reason a wild-type mitogenic report on a left-sided tumour is read as ligand dependence rather than as an absence.
It made acquired resistance a measurable, plasma-readable event, and it is the origin of anti-EGFR rechallenge strategies guided by ctDNA clearance of the resistant clone.
Shares Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
Shares Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
Shares Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
Shares KRAS G12C-mutant colorectal cancer, Colorectal cancer and the tags colorectal, trialist.
Shares BRAF V600E-mutant colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy.
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.